Pharmaceuticals Philippines

Philippines Dengue Vaccines Market Analysis, 2024–2034

Philippines Dengue Vaccines Market Industry Trends and Forecast to 2034: Segmented by (Product, Age, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Philippines · 2024–2034 · estimates

Values shown here are estimates. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $1.6 Mn Estimated value
Estimate 2025 $1.9 Mn 0.3% of the global market
Projected 2034 $10.4 Mn 447.8% Adds $8.5 Mn over 9 forecast years
CAGR 2025–2034 20.8% Faster than 88% of 180 Pharmaceuticals markets here
Key players 5
  • Philippines is 0.26% of the global market.
  • In APAC, the largest is China at $55.3 Mn.
  • Fastest growing: India at 22.9% a year.
  • Philippines ranks 6th of 10 by size in APAC.

Market size projection

Philippines

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$8.5 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Dengue Vaccines Market market size by year, Philippines
YearMarket sizeChange that yearSince 2025
2024 (estimate) $1.6 Mn — —
2025 (base) $1.9 Mn +$0.3 Mn —
2026 (forecast) $2.3 Mn +$0.4 Mn +20.8%
2027 (forecast) $2.8 Mn +$0.5 Mn +45.9%
2028 (forecast) $3.3 Mn +$0.6 Mn +76.3%
2029 (forecast) $4.0 Mn +$0.7 Mn +112.9%
2030 (forecast) $4.9 Mn +$0.8 Mn +157.2%
2031 (forecast) $5.9 Mn +$1.0 Mn +210.7%
2032 (forecast) $7.1 Mn +$1.2 Mn +275.4%
2033 (forecast) $8.6 Mn +$1.5 Mn +353.5%
2034 (forecast) $10.4 Mn +$1.8 Mn +447.8%

Estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

The Philippines Dengue Vaccines Market Analysis Executive Summary

Dengue vaccines protect against dengue fever, a mosquito-borne disease spreading fast in tropical and warming regions.

Key segments of the dengue Vaccines market include product (Live Attenuated Vaccines and Candidate Vaccines) and age (Children, Adolescents and Adults).

Philippines Dengue Vaccines Market Dynamics

Market Growth Drivers

Rising antimicrobial resistance, outbreaks of new and returning diseases, climate change spreading infections and strong global funding for prevention are driving the dengue Vaccines market.

Opportunity

New vaccines, rapid tests and public-private funding for neglected diseases give the dengue Vaccines market room to grow, especially in Asia, Africa and Latin America.

Market Restraints

Low prices in poorer markets, weak returns for new antibiotics, vaccine hesitancy and cold-chain problems hold back the dengue Vaccines market.

Competitive Landscape for Dengue Vaccines Market in Philippines

The dengue Vaccines market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Dengue Vaccines Market in Philippines

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for dengue Vaccines. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Philippines.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Dengue Vaccines right now, from free public sources.

Clinical trials

2 active trials in the Philippines

Recruiting, about to start, or running now.

Top trial sponsors (worldwide)

  1. Takeda Pharmaceutical Company Ltd 5 active trials on ClinicalTrials.gov (opens in a new tab)
  2. Sanofi 2 active trials on ClinicalTrials.gov (opens in a new tab)

Source: ClinicalTrials.gov, Industry lead sponsors of active studies found with this market's trial search, worldwide. Retrieved 13 Nov 2026.

See every trial on ClinicalTrials.gov (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Dengue Vaccines in context

The Philippines compared

  • Health spending per person: 194 US$ per person (2023). World: 1,317 US$ per person (2023). 8th highest of the 15 countries we cover in APAC.[1]
  • Doctors: 0.79 per 1,000 people (2021). World: 1.86 per 1,000 people (2022). 9th highest of the 15 countries we cover in APAC.[2]
  • People aged 65 and over: 5.7% of people (2025). World: 10.4% of people (2025). 14th highest of the 16 countries we cover in APAC.[3]

Questions, answered with public data

How many clinical trials on Dengue Vaccines are running in the Philippines?
2 studies are recruiting, active or about to start in the Philippines.[4]
How much research is published on Dengue Vaccines?
PubMed lists 165 papers added since January 2021 that match this market, worldwide.[5]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 13 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 13 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 13 Nov 2026.

[4] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the Philippines. Retrieved 12 Nov 2026.

[5] PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.

Free data on this topic

Back to Catalogue

Related Pharmaceuticals reports in Philippines

See all

Related on vaccines and infectious diseases

See the topic